Comprehensive characterization of MET exon 14 skipping mutations in non-small cell lung cancer.

🎯 Background & Rationale

• Clinical knowledge gap: MET exon 14 skipping mutations (METex14) are established oncogenic drivers in non-small cell lung cancer (NSCLC), but their genomic complexity and evolutionary role in therapy resistance remain incompletely characterized.
• Resistance implications: METex14 can act both as a primary driver and as an acquired resistance mechanism following treatment with epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors.
• Therapeutic relevance: Understanding concurrent genomic alterations, intra-tumoral heterogeneity, and secondary resistance pathways to MET inhibitors like crizotinib and savolitinib is vital for optimizing clinical outcomes.

👥 Study Design & Population

• Study type: A large-scale retrospective genomic and clinical cohort study analyzing multocenter patient data.
• Screening cohort: A total of 57,521 patients with NSCLC underwent targeted next-generation sequencing using a 425 pan-cancer gene panel (GeneseeqPrime) between July 2016 and May 2022.
• Analysis population: 585 patients harboring METex14 mutations were identified (prevalence of 1.02%), comprising 556 baseline samples, 53 samples resistant to MET inhibitors, and 16 samples resistant to EGFR or ALK inhibitors.

📈 Methodology & Rigor

• Genomic profiling: Comprehensive targeted next-generation sequencing was performed on DNA extracted from formalin-fixed paraffin-embedded tissue, pleural effusion, and plasma liquid biopsy samples.
• Advanced metrics: Chromosomal instability and intra-tumoral heterogeneity were calculated using specific copy number and variant allele frequency proportions, with optimal cut-offs determined via maximally selected rank statistics.
• Rigorous validation: Orthogonal validation using droplet digital precision polymerase chain reaction demonstrated 100% overall percent agreement across a wide variant allele frequency range, and multiple hypothesis testing utilized Benjamini-Hochberg false discovery rate adjustments.

🔬 Key Findings

• Prevalence patterns: METex14 mutations exhibited a prevalence of 1.02%, with significantly higher incidences observed in pulmonary sarcomatoid carcinoma (9.7%) and adenosquamous carcinoma (4.0%).
• Baseline co-alterations: The most frequent concurrent genomic alterations at baseline included TP53 mutations (40.8%), CDK4 amplifications (16.0%), and EGFR mutations (12.4%).
• Crizotinib outcomes: Concurrent MET amplification, MYC amplification, high chromosomal instability, and high intra-tumoral heterogeneity were significantly associated with shorter progression-free survival in crizotinib-treated patients.
• Resistance mechanisms: Acquired resistance to MET tyrosine kinase inhibitors was driven by on-target MET D1228X or Y1230X point mutations, off-target RTK/RAS/MAPK or PI3K/AKT pathway alterations, and an exploratory FGFR3::TACC3 fusion linked to savolitinib resistance.
• EGFR/ALK progression: METex14 was identified in 16 patients following disease progression on prior EGFR or ALK inhibitors, highlighting its role as a bypass resistance mechanism.

⚖️ Critical Appraisal

• Retrospective bias: The analysis relied heavily on retrospective data and a shifting sample distribution from tissue at baseline to liquid biopsies at progression, which may introduce detection bias.
• Cohort limitations: The sample size for savolitinib-treated patients (n=11) and matched post-progression pairs was relatively small, rendering findings regarding savolitinib resistance exploratory.
• Missing longitudinal data: The lack of paired baseline tissue for the EGFR/ALK-TKI resistance cohort limits the ability to definitively separate de novo mutations from clonal selection of pre-existing ultra-low frequency subclones.

💡 The Clinical Bottom Line

• Dynamic re-biopsy: Interventional pulmonologists must utilize repeat tissue acquisition or liquid biopsies at disease progression to capture actionable bypass alterations and secondary MET resistance mutations.
• Biomarker awareness: The presence of concurrent baseline alterations like MET amplification or high chromosomal instability signals aggressive tumor behavior and inferior responses to standard MET tyrosine kinase inhibitors.
• Resistance surveillance: METex14 mutations can emerge as escape mechanisms following EGFR or ALK inhibitor therapy, necessitating comprehensive molecular profiling beyond standard resistance panels.